Recent

% | $
Quotes you view appear here for quick access.

Xinyuan Real Estate Co., Ltd. Message Board

rvga128 1382 posts  |  Last Activity: 1 hour 38 minutes ago Member since: Dec 5, 2003
  • rvga128 rvga128 May 30, 2015 2:18 PM Flag

    They need ADXS as much as MERCK needs. Durability as J & E calls and sustainability as I would prefer.

  • Reply to

    OT: The " OTHER " Adage Holding

    by me2yousee May 30, 2015 1:21 PM
    rvga128 rvga128 May 30, 2015 2:17 PM Flag

    That is starving tumors of essential nutrition.

  • Reply to

    Speaking of soft bashing...

    by donjayouworry May 30, 2015 1:30 PM
    rvga128 rvga128 May 30, 2015 2:14 PM Flag

    Nice. That was a great dig and now we can clearly see the agenda. Thank you.

  • rvga128 rvga128 May 30, 2015 1:57 PM Flag

    chinaman.nyc2003 • 3 hours ago Flag
    2users liked this postsusers disliked this posts0Reply
    adxs does not need merck,,,,merck and bmy need adxs badly.
    first the outstanding preclinical data that suggests lmllo is superior to anti pd1. now the human anti pd1 data that suggest monotherapy of anti pd1 simply does not cut it. market reaction to bmy stock says it all. market reaction to adxs stock yesterday in the view of bmy news is also telling.

    the setup of adxs and merck is simply a get together of convenience. bmy needs to get into the picture for its own benefit and survival. adro's vaccine is dead fish flapping (gvax trial stopped and abandoned). adxs vac is the real deal. --
    -------------------------------------------------------------------
    That is how much bashing- Chinaman upto. Just pointing. You have a long want to go IMHO- but it does not matter.

  • Can change the microenvironment by acting on dendritic cells, macrophages, Treg cells and sustain the antitumor effects. Great way to deliver a payload of antigen to help immune cells to identify the tumor antigens, help thwart immune escape mechanisms of tumor cells and sustain this. Durability of response. Can work with all other agents.

  • Reply to

    Significance of ADXS' Corporate Logo: Trojan Horse

    by fbg0316 May 29, 2015 10:02 PM
    rvga128 rvga128 May 30, 2015 10:45 AM Flag

    Up for those interested in knowing why LmLLO will be a hit. Check the posts of mine on this thread. ood to know and ever happy to share with all LONGs and STRONG.

  • Among patients with a far more common form of lung cancer called non-quamous non-small-cell lung cancer, Opdivo was shown to reduce the risk of death 27% compared to a placebo. Patients with tumors expressing high levels of the protein PD-1 lived even longer.
    In a study of 132 patients with head and neck cancer, Merck’s Keytruda demonstrated a tumor response rate of 25%, or more than double the response typically seen with Eli Lilly’s (LLY) Erbitux.
    Merck’s Keytruda demonstrated 62% tumor shrinkage in a phase 2 study of 48 patients with advanced colon cancer containing a newly discovered genetic biomarker.
    Among patients with advanced liver cancer using Bristol’s Opdivo, the overall survival rate at 12 months was 62%.

  • rvga128 rvga128 May 29, 2015 10:38 PM Flag

    Seems like a venture capital fund.

  • Reply to

    Significance of ADXS' Corporate Logo: Trojan Horse

    by fbg0316 May 29, 2015 10:02 PM
    rvga128 rvga128 May 29, 2015 10:09 PM Flag

    LmLLO may help to thwart Dendritic Cell dysfunction and help with tumor microenvironment changes.
    Tumor cells by releasing IL-10, IL-6, M-CSF, vascular endothelial growth factor (VEGF), gangliosides and/or prostanoids, tumours can prevent Dendritic cells (DC) differentiation and function in vitro and in vivo. This lack of maturation of DCs is responsible for ineffective antigen presentation.
    These cells called as APCs initiate the immune mechanisms. Tumor tissue in different cancers has immature and dysfunctional DCs while peri-tumor tissue has functional and mature DCs.
    This may explain the microenvironment changes induced by LmLLO (Vector with tumor antigen

  • Reply to

    Significance of ADXS' Corporate Logo: Trojan Horse

    by fbg0316 May 29, 2015 10:02 PM
    rvga128 rvga128 May 29, 2015 10:08 PM Flag

    May be LmLLO also does this:
    May have a role in decreasing M2 Phenotype of Tumor Associated Macrophages and increasing M1 phenotype of anti-tumor associated Macrophages.
    This may actually decrease naive T cells being activated to become iTreg (inducible T regs as vs natural T regs)
    These iTregs are responsible for proliferation of T regs in tumor tissue and are responsible for suppression of both innate and adaptive immune responses.

  • Reply to

    Keytruda in Bladder Cancer

    by rvga128 May 29, 2015 8:14 PM
    rvga128 rvga128 May 29, 2015 10:03 PM Flag

    Glad to share. We are going to collaborate with several BPs and in several different cancers.

  • A fourth of patients with PD-1-positive advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor pembrolizumab, data from an ongoing trial showed.

    Seven of 28 evaluable patients (25%) responded to treatment, including three complete responses (10.7%). Patients had durable responses that ranged from 16 weeks to more than a year. Additionally, pembrolizumab was generally well tolerated among patients with urothelial cancer, as reported at the 2015 American Urological Association annual meeting.

    “In this heavily pretreated population, pembrolizumab provided a median overall survival of 12.7 months and a 12-month overall survival of 54.7%,” Shilpa Gupta, MD, a genitourinary oncologist at Moffitt Cancer Center in Tampa. “These results support the ongoing development of pembrolizumab for the treatment of urothelial cancer.”

    Ongoing clinical development includes a phase III trial comparing pembrolizumab versus paclitaxel, docetaxel, or vinflunine in patients whose disease progressed or recurred following treatment with platinum-based chemotherapy. Additionally, a phase II trial is evaluating pembrolizumab in patients with advanced urothelial cancer ineligible for platinum chemotherapy.

    The PD-1 receptor antagonist pembrolizumab received FDA approval in 2014 for unresectable or metastatic melanoma and progression following treatment with ipilimumab and (if indicated) a BRAF inhibitor. The FDA approved dose of the drug in patients with melanoma is 2 mg/kg once every 3 weeks.
    -

  • Reply to

    This is good for Advaxis and Merck.

    by fbg0316 May 29, 2015 7:59 PM
    rvga128 rvga128 May 29, 2015 8:13 PM Flag

    A fourth of patients with PD-1-positive advanced urothelial cancer had objective responses to treatment with the immune checkpoint inhibitor pembrolizumab, data from an ongoing trial showed.

    Seven of 28 evaluable patients (25%) responded to treatment, including three complete responses (10.7%). Patients had durable responses that ranged from 16 weeks to more than a year. Additionally, pembrolizumab was generally well tolerated among patients with urothelial cancer, as reported at the 2015 American Urological Association annual meeting.

    “In this heavily pretreated population, pembrolizumab provided a median overall survival of 12.7 months and a 12-month overall survival of 54.7%,” Shilpa Gupta, MD, a genitourinary oncologist at Moffitt Cancer Center in Tampa. “These results support the ongoing development of pembrolizumab for the treatment of urothelial cancer.”

    Ongoing clinical development includes a phase III trial comparing pembrolizumab versus paclitaxel, docetaxel, or vinflunine in patients whose disease progressed or recurred following treatment with platinum-based chemotherapy. Additionally, a phase II trial is evaluating pembrolizumab in patients with advanced urothelial cancer ineligible for platinum chemotherapy.

    The PD-1 receptor antagonist pembrolizumab received FDA approval in 2014 for unresectable or metastatic melanoma and progression following treatment with ipilimumab and (if indicated) a BRAF inhibitor. The FDA approved dose of the drug in patients with melanoma is 2 mg/kg once every 3 weeks.
    -

  • ivolumab (Opdivo) generated antitumor responses in nearly 20% of patients with advanced hepatocellular carcinoma (HCC) in a small study that suggests a promising role for the immunotherapy agent in a malignancy with dismal outcomes,1 researchers said at the 2015 ASCO Annual Meeting. Eight of 42 evaluable patients who participated in the phase I/II study achieved a complete (n = 2) or partial (n = 6) response, as defined by RECIST criteria, lead investigator Anthony B. El-Khoueiry, MD, said during a press briefing. El-Khoueiry is an associate professor of clinical medicine and the phase I program director at the University of Southern California Norris Comprehensive Cancer Center in Los Angeles. Notably, El-Khoueiry said, the responses were durable, extending beyond 9 months in 7 of the 8 responders. Tumor growth stabilized in 48% of patients, with the longest duration extending beyond 17 months. Additionally, 62% of patients in the study were still surviving with HCC at 12 months. The study is the first to demonstrate that a PD-1 inhibitor can be effective in patients with HCC and, even though the study cohort was small, the results compare favorably with existing treatment options, El-Khoueiry indicated. He said the next step in the research is an expansion phase of the trial that will evaluate the drug in a larger group of patients.2 El-Khoueiry noted that sorafenib, which inhibits VEGFR and other kinases, is the only FDA-approved systemic therapy for patients with advanced HCC, with an average overall survival of 7 months to 11 months. “The response rate with the standard of care, which is sorafenib, is 2% to 3%,” he said. "In the setting of patients who have already been treated with sorafenib it’s about 30% who are usually alive at 12 months.” There is a pressing need for new therapies for patients with HCC, most of whom present with advanced disease, El-Khoueiry indicated. He said HCC is the second most frequent cause of cancer-related death worldwide, and that approximately 780,000 new cases are diagnosed annually. - See more at:

  • Reply to

    This is good for Advaxis and Merck.

    by fbg0316 May 29, 2015 7:59 PM
    rvga128 rvga128 May 29, 2015 8:07 PM Flag

    n a multisite study offering the largest experience to date of how immunotherapy can be deployed in patients with head and neck cancer, the anti-PD-1 antibody pembrolizumab produced broad and durable responses in patients with advanced disease. Fifty-six percent of patients in the study experienced some tumor shrinkage with pembrolizumab, and 86% of patients continued to respond to treatment at data cutoff March 23, 2015. Overall, pembrolizumab produced an overall response rate (ORR) of 25%, and it proved active in both HPV-positive and HPV-negative patients. “The efficacy was remarkable—pembrolizumab seems to be roughly twice as effective, when measured by response, as our only targeted therapy, cetuximab,” said Tanguy Seiwert, MD, an assistant professor of medicine and associate leader of the head and neck cancer program at the University of Chicago, who presented the results in a press briefing May 29 at the 2015 ASCO Annual Meeting. “We have high hopes that immunotherapy will change the way we treat head and neck cancer.” Recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) has a poor prognosis with a median overall survival (OS) of only 13 months in patients treated in the first-line setting and 6 months in previously treated patients—the majority of patients in this study, which builds on earlier findings from the KEYNOTE-012 study (NCT01848834). In that study, pembrolizumab administered at 10 mg/kg every 2 weeks, had a 20% response rate in patients with advanced HNSCC whose tumors were PD-L1–positive. Findings of the study reported here are from an expansion cohort involving 132 advanced HNSCC patients who were recruited regardless of their PD-L1 or HPV status. Importantly, said Seiwert, patients in this cohort received a fixed dose of pembrolizumab (200 mg/every 3 weeks), representing “a very convenient dosing schedule.” -

  • Reply to

    This is good for Advaxis and Merck.

    by fbg0316 May 29, 2015 7:59 PM
    rvga128 rvga128 May 29, 2015 8:06 PM Flag

    Treatment with the PD-1 inhibitor pembrolizumab (Keytruda) demonstrated high response rates in patients with heavily pretreated colorectal cancer who harbored genetic defects in mismatch repair (MMR), according to findings from an ongoing phase II study presented at the 2015 ASCO Annual Meeting. In patients with MMR deficiencies the objective response rate (ORR) was 62% compared with 0% in patients with MMR-proficient tumors. Median progression-free survival (PFS) and overall survival (OS) were not reached, with many patients responding to treatment for longer than 12 months in the MMR-deficient arm. "This is the first study to use genetics in a prospective manner to guide immunotherapy," lead author Dung T. Le, MD, an assistant professor of oncology at Johns Hopkins Kimmel Cancer Center, said during a press briefing. "Mismatch repair deficient tumors are highly responsive to checkpoint blockade with anti-PD-1." Findings from the analysis were simultaneously published in The New England Journal of Medicine (NEJM); however, data at the ASCO meeting were from a more up-to-date analysis that was conducted on May 8, 2015. In the 3-arm study, pembrolizumab was administered at 10 mg/kg every 2 weeks to patients with colorectal cancer (CRC) who were MMR-deficient (n = 13) and MMR-proficient (n = 25). Additionally, a separate arm looked at pembrolizumab in patients with MMR-deficient non-CRC malignancies (n = 10). MMR and microsatellite instability testing was conducted using PCR and IHC, which are standard tests conducted for patients with CRC in order to detect Lynch syndrome. "Mismatch repair deficiency is easily determined using an existing commercially available test," Le said. "In terms of cost, the tests run in the 100 of dollars, not the thousands that panels cost." The primary endpoint of the study was immune-related PFS and response rate at 20 weeks. Secondary endpoints focused on OS, PFS, and disease control rate (DCR; complete response, partial response, plus stable disease). Response and survival were assessed by RECIST criteria in addition to immune-related criteria. In the first 48 patients analyzed from the study, those with MMR-deficient CRC experienced an ORR of 62% and a DCR of 92%. The ORR was 0% and the DCR was 16% in MMR-proficient tumors. After a median treatment duration of 5.9 months, no patients in the MMR-deficient group who responded had progressed. OS and PFS were not reached in the MMR-deficient group versus a median PFS of 2.3 months and an OS of 7.6 months in the MMR-proficient group. In patients with MMR-deficient non-CRC tumors, the ORR was 60% and the DCR was 70%. The adverse events seen in the study were consistent with other studies of pembrolizumab. The most common side effects were rash/pruritus (17%), pancreatitis (15%), and thyroiditis/hypothyroidism (10%). -

  • rvga128 rvga128 May 29, 2015 2:09 PM Flag

    Viralytics: Could the common cold cure cancer? That’s the question Viralytics has set out to answer with its specially formulated version of coxsackievirus, better known as the cold virus. At ASCO, the Aussie company will present data from a mid-stage trial in 57 patients with advanced melanoma. The company will report that 21 of the patients reached the primary endpoint of the trial—achieving immune-related progression-free survival at six months. Further clinical studies are underway, the company reports
    --------------------------------------------------------------------
    But it is Aussie Company and in Melanoma.

  • Reply to

    I just shorted 10,000 shares at $25

    by cheungmao5455 May 29, 2015 1:36 PM
    rvga128 rvga128 May 29, 2015 2:05 PM Flag

    cheungmao5455
    1 post | Last Activity: 27 minutes ago
    Member since: May 29, 2015
    3 months

    Sort: Newest | Oldest | Highest Rated Expand all messages
    .0
    users liked this posts

    users disliked this posts
    8
    Reply

    I just shorted 10,000 shares at $25

    by cheungmao5455 • 27 minutes ago
    .

    Gonna be rich!
    --------
    With ID born today, and we can agree that your DREAMS are true, or is it HALLUCINATIONs and DELUSIONS of GRANDEUR.

  • rvga128 rvga128 May 29, 2015 1:09 PM Flag

    So your MOTIVE is social service. I do not believe IT.

XIN
2.97-0.01(-0.34%)Jun 3 4:00 PMEDT